상단메뉴 바로가기 본문 바로가기
닫기닫기
전체 검색

고영일 Koh, Youngil

내과학교실 혈액종양내과
SNU MEDICINE SNU MEDICINE 고영일 Koh, Youngil Seoul National University College of Medicine
직위
교수
사무실
서울대학교병원
이메일
go01@snu.ac.kr
홈페이지
https://snu.elsevierpure.com/en/persons/young-il-koh
As a hematologist, I am focusing on lymphoid malignancies including lymphoma, myeloma and acute lymphoblastic leukemia. Next generation sequencing data generation and interpretation in the field of cancer is main methodology for research. 학술활동 RTK-RAS pathway mutation is enriched in myeloid sarcoma. Blood Cancer J. 2018 May 23;8(5):43. Identification of Novel Functional Variants of SIN3A and SRSF1 among Somatic Variants in Acute Myeloid Leukemia Patients. Mol Cells. 2018 May 31;41(5):465-475. A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTKorea. Cancer Med. 2018 May;7(5):1814-1823. Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high-risk multiple myeloma in Asian patients. Cancer Med. 2018 Mar;7(3):831-841. Which donor is better when a matched donor is not available domestically? Comparison of outcomes of allogeneic stem cell transplantation with haploidentical and international donors in a homogenous ethnic population. Leuk Res. 2018 Jun;69:31-38 Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma. Blood Adv. 2017 Oct 27;1(24):2138-2146 Physicians' preferences and perceptions regarding donor selection in allogeneic stem cell transplantation in Korea when a matched domestic donor is not available. Blood Res. 2017 Mar;52(1):31-36 Identification of somatic mutations using whole-exome sequencing in Korean patients with acute myeloid leukemia. BMC Med Genet. 2017 Mar 1;18(1):23 Salvage therapy for acute chemorefractory leukemia by allogeneic stem cell transplantation: the Korean experience. Ann Hematol. 2017 Apr;96(4):605-615 BCR-ABL translocation as a favorable prognostic factor in elderly patients with acute lymphoblastic leukemia in the era of potent tyrosine kinase inhibitors. Haematologica. 2017 May;102(5):e187-e190